Physician
Capitol Infectious Disease Associates
Capitol Infectious Disease Associates was paid $770K by Medicaid between Jan 2018 and Dec 2024, across 8 billing codes. Its largest line is 99232, hospital visit by a doctor, follow-up day — 29% of everything it billed.
33Billing provider infoCAPITOL INFECTIOUS DISEASE ASSOCIATES
EAST LANSING, MI 48823
EAST LANSING, MI 48823
33aNPI1497205546assigned 10/12/2016
33bProvider typeInfectious Disease Physician
28Total paid$770K
24GClaims10,431
24DCodes billed8
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Infectious Disease Physician providers in Michigan
Rank by total paid#9 of 43
Median peer was paid$278K
This provider vs. median2.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 379 | $18K | |
| 2019 | 54 | $3K | |
| 2020 | 601 | $36K | |
| 2021 | 1,400 | $94K | |
| 2022 | 1,802 | $92K | |
| 2023 | 3,243 | $361K | |
| 2024incomplete | 2,952 | $166K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99232 | Hospital visit by a doctor, follow-up daySubsequent hospital care, per day, moderate complexity | 29% | 5,197 | 1,168 | $222K |
| J2406 | Injection, oritavancin (kimyrsa), 10 mg | 24% | 56 | 37 | $182K |
| 99233 | Hospital visit by a doctor, follow-up day (complex)Prolong inpt eval add15 m | 20% | 2,604 | 931 | $153K |
| 99223 | Prolong inpt eval add15 m | 16% | 1,239 | 1,190 | $125K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 8.1% | 1,054 | 844 | $62K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 1.8% | 35 | 35 | $14K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.2% | 234 | 219 | $10K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 12 | 12 | $3K |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialABBAS, MUJAHED (OWNER / AUTHORIZED OFFICIAL)